New shot shows promise for tough skin cancer in japanese patients
NCT ID NCT06041802
First seen Dec 29, 2025 · Last updated Apr 28, 2026 · Updated 19 times
Summary
This study tests a new drug combination (pembrolizumab plus hyaluronidase) given as a shot under the skin for Japanese patients with advanced skin cancer that has spread or cannot be removed by surgery. The goal is to see if the drug can shrink tumors and control the disease. About 19 participants will be enrolled, and the study focuses on safety and how well the treatment works.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Cancer Institute Hospital of JFCR ( Site 0018)
Koto, Tokyo, 135-8550, Japan
-
Chiba University Hospital ( Site 0001)
Chiba, 260-8677, Japan
-
Keio University Hospital ( Site 0010)
Tokyo, 1608582, Japan
-
Nagoya University Hospital ( Site 0003)
Nagoya, Aichi-ken, 466-8560, Japan
-
National Cancer Center Hospital ( Site 0007)
Chuo-ku, Tokyo, 104-0045, Japan
-
National Hospital Organization Kagoshima Medical Center ( Site 0013)
Kagoshima, 892-0853, Japan
-
National Hospital Organization Kyushu Cancer Center ( Site 0017)
Fukuoka, 811-1395, Japan
-
Niigata Cancer Center Hospital ( Site 0005)
Niigata, Niigata, 951-8566, Japan
-
Osaka Prefectural Hospital Organization Osaka International Cancer Institute ( Site 0009)
Osaka, 541-8567, Japan
-
Saitama Medical University International Medical Center ( Site 0008)
Hidaka, Saitama, 350-1298, Japan
-
Sapporo Medical University Hospital ( Site 0002)
Sapporo, Hokkaido, 060-8543, Japan
-
Shimane University Hospital ( Site 0014)
Izumo, Shimane, 693-8501, Japan
-
Shinshu University Hospital ( Site 0011)
Matsumoto, Nagano, 390-8621, Japan
-
Shizuoka Cancer Center ( Site 0004)
Nagaizumi-cho,Sunto-gun, Shizuoka, 411-8777, Japan
-
Tohoku University Hospital ( Site 0019)
Sendai, Miyagi, 980-8574, Japan
-
University Hospital,Kyoto Prefectural University of Medicine ( Site 0012)
Kyoto, 602-8566, Japan
-
Wakayama Medical University Hospital ( Site 0015)
Wakayama, 641-8510, Japan
-
Yokohama City University Hospital ( Site 0016)
Yokohama, Kanagawa, 236-0004, Japan
Conditions
Explore the condition pages connected to this study.